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We reviewed relevant literature about SDM with additional focus on pa-
tient and radiotherapy-nurse perspectives. Interview were held with nati-
onal and local experts on SDM in non-radiotherapy domains. 
Communicating of risk and benefit was a topic of great relevance and hence 
it was important to define the exact tool needed for the SDM consultation. 
A decision aid was developed in cooperation with clinical colleagues. Two 
patients undergoing radiotherapy were asked for feedback. The decision aid 
was revised and three other patients were asked for feedback during their 
routine follow-up consultations.
No specifically relevant literature on SDM in an anal cancer radiotherapy 
setting was found. For our first pilot trial, the consensus was to design 
a simple qualitative decision aid.  
All 5 patients asked had critical and useful points of view on the 
decision aid. Patients reported feeling that they understood 
the options presented and would have been able to make the 
choice they were asked for. 
Importantly, all 5 patients interviewed said they would 
like to make the choice themselves. Three patients said 
they would prefer more information on late side e
ffects before their radiotherapy treatment, to be 
able to make an informed choice. 
The final decision aid consisted of a visual 
illustration, side-by-side comparison 
of common questions and two hy-
pothetical patient stories. 
Material number: 124830, September 2016, Lillebaelt Hospital
In curative anal cancer radiotherapy there is a 
possible trade-off between the risks and benefits of 
a higher or lower radiation dose. 
A pilot trial of elective target dose de-escalation for anal 
cancer patients, incorporating patient preferences, was 
introduced and a decision aid had to be developed to support 
the decision making for the patient according to radiation dose, 
side effects  and quality of life. 
The decision aid was inspired by the recognized option grid 
developed by the group of Glyn Elwyn. 
HIGHER RADIATION DOSE:
I want to increase my chance 
of the tumor completely disap-
pearing. At the same time, I am 
increasing my risk of side 
effects, which might affect my 
quality of life.
LOWER RADIATION DOSE:
I want to decrease my risk of 
side effects, and possibly increase 
my chance for a good quality of life.
The chance that the tumor com-
pletely disappears will  decrease 
slightly.
PLEASE NOTE: 
For any choice, it is not 
guaranteed that your tumor will 
completely disappear or that you will 
experience fewer side effects.
You will be choosing between 
increasing the chance that the tu-
mor disappears OR decreasing the 
chance that you experience 
side effects.
In shared decision-making (SDM), clinicians and patients participate in an opti-
ons-based conversation, such that joint preferences and mutually desired out-
comes can be incorporated into treatment decisions. 
There is compelling evidence that patients who are active participants in 
managing their health care have better outcomes than patients who are 
passive recipients of care. 
The use of decision aids supports SDM, and this contribution describes the 
practical processes and learning outcomes of developing a decision aid in a 
clinical setting. 
Significant clinical learning outcomes were SDM theory, complexity of designing de-
cision aids and awareness of the process of involving patients as partners in their 
radiotherapy treatment. 
We observed a paucity of published data on late effects relating to patient-speci-
fic outcomes. This emphasises the need to orient research outcomes into a more 
patient-centred direction. 
Patients were effective partners in the development of the decision aid; patient 
feedback was essential for refining the decision aid and educating clinical staff. 
Our SDM protocol has received ethics approval, and four patients is already enroled.
DECISION AID
FREQUENTLY ASKED QUESTIONS HIGHER RADIATION DOSE
How many times should I have 
radiotherapy?
Will my chemotherapy be 
affected of my choice?
What is my risk of acute side 
effects?
What are my risks of metastases?
What are my risk of going through 
surgery and get a stoma?
What are the long term side 
effects?
What is my risk of long term side 
effects?
LOWER RADIATION DOSE
You will be treated in 28 
episodes, 5 days a week.
Your chemotherapy will not be affected by your choice. 
However, we recommend that you do not opt out of 
chemotherapy, if you choose the lower radiation dose.
You have the same risk with either option. Acute side 
effects are specifically diarrhea, excoriation and pain 
around your anus.
Your risk of metastases is not higher if you choose the 
lower radiation dose.
The risk is the same but 
has different causes. At the 
higher dose, your risk of 
surgery and a stoma will be 
higher due to long term side 
effects
The risk is the same but 
has different causes. At 
the lower dose, your risk of 
surgery and a stoma will be 
higher due to the tumor not 
completely disappearing.
Chronic ulceration and bleeding from the rectum. Inability 
to hold stool. Diarrhea or constipation. Mucus or blood in 
the stool. Fatigue fractures in the bones of the pelvis. Pain 
in the pelvis. Frequent need to urinate.
For women: narrowing of the vagina or dryness. 
For men: erectile dysfunction.
The risk of long term side 
effects is generally higher. 
In particular, the risk of 
chronic ulceration and 
bleeding in the gut is slight-
ly higher. The sphincter 
muscle of the rectum can 
be affected more, and thus 
the risk of urgently needing 
to defecate is higher.
The risk of long term side 
effects is generally smaller.
In particular, the risk of 
chronic ulceration and 
bleeding in the gut are 
slightly lower.
The sphincter muscle can 
be spared more, and the 
risk of urgently needing to 
defecate is lower.
You will be treated in 
25 episodes, 5 days a week.
DECISION AID
RADIOTHERAPY DEPARTMENT, VEJLE HOSPITAL
Mr. Hansen is 67 years old and has been diagno-
sed with anal cancer. 
He is recommended for radiotherapy treatment, 
and has been discussing risks and benefits with 
the doctors and the nurses in the department. 
He has also been reading about the illness and 
possible side effects.
A couple of years ago, Mr. Hansen retired and 
he is enjoying life with his wife. Mr. Hansen has 
a big family with lots of grandchildren, and the 
MRS. SOERENSEN CHOOSES THE LOWER RADIATION DOSE
Mrs. Soerensen is 73 years old and has been diagnosed with anal cancer. 
She is recommended for radiotherapy treatment, and has been discussing risks and 
benefits with the doctors and the nurses in the department. She has also been reading 
about the illness and possible side effects.
Mrs. Soerensen lost her husband 10 years ago. She has many friends and enjoys so-
cializing a lot. It means very much to Mrs. Soerensen, that she looks nice and that she 
can go out whenever she wants. She does gymnastics and swims with her friends. 
Mrs. Soerensen would be really sad if she had to use diapers due to bleeding or faecal 
incontinence since she feels it will limit her social activities. This is why Mrs. Soeren-
sen chose the lower radiation dose.
HR. HANSEN CHOOSES 
THE HIGHER RADIATION DOSE
time he spends with his family means a lot to him. He enjoys staying at home and he 
feels safe with his family. 
For many years, Mr. Hansen and his wife have not been active sexually, therefore he is 
not concerned of the risk of erectile dysfunction after the radiotherapy treatment. 
Overall, he wanted to increase the chance of getting cured from the cancer by radiati-
on therapy, and therefore he chose the higher radiation dose.
You’ve now had a conversation with your doctor about the radiotherapy treatment. We can offer 
different options for your treatment. 
We can vouch for the safety of either treatment option below, as they are both allowed by the 
national Danish guidelines.
There will be different advantages and disadvantages for you to consider. Therefore, it’s impor-
tant to be aware of your preferences when you make your choice of treatment. These next pages 
are intended to help you make your choice.
ACUTE SIDE EFFECTS: Acute side effects occur during the treatment pha-
se and typically go away a few weeks after treatment is finished.
LONG-TERM SIDE EFFECTS: Occurs from 3 months after your treatment. 
Some long-term side effects are enduring and could be difficult to treat.
RADIOTHERAPY DEPARTMENT, VEJLE HOSPITAL
DECISION AID
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